Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment
  
Lilly presented Phase II data for eloralintide at ObesityWeek 2025. (Shutterstock)

More from Clinical Trials

More from R&D